Synonym
Xamoterol fumarate; ICI1185876; ICI-1185876; ICI 1185876
IUPAC/Chemical Name
Bis(N-(2-((2-hydroxy-3-(4-hydroxyphenoxy)propyl)amino)ethyl)morpholine-4-carboxamide) fumarate
InChi Key
QEDVGROSOZBGOZ-WXXKFALUSA-N
InChi Code
InChI=1S/2C16H25N3O5.C4H4O4/c2*20-13-1-3-15(4-2-13)24-12-14(21)11-17-5-6-18-16(22)19-7-9-23-10-8-19;5-3(6)1-2-4(7)8/h2*1-4,14,17,20-21H,5-12H2,(H,18,22);1-2H,(H,5,6)(H,7,8)/b;;2-1+
SMILES Code
O=C(N1CCOCC1)NCCNCC(O)COC2=CC=C(O)C=C2.O=C(N3CCOCC3)NCCNCC(O)COC4=CC=C(O)C=C4.O=C(O)/C=C/C(O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
|
Solvent |
mg/mL |
mM |
| Solubility |
| Soluble in DMSO |
0.0 |
100.00 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
794.86
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Ardestani PM, Evans AK, Yi B, Nguyen T, Coutellier L, Shamloo M. Modulation of neuroinflammation and pathology in the 5XFAD mouse model of Alzheimer's disease using a biased and selective beta-1 adrenergic receptor partial agonist. Neuropharmacology. 2017 Apr;116:371-386. doi: 10.1016/j.neuropharm.2017.01.010. Epub 2017 Jan 13. PMID: 28089846; PMCID: PMC5385159.
2: Marlow HF. Xamoterol, a beta 1-adrenoceptor partial agonist: review of the clinical efficacy in heart failure. Br J Clin Pharmacol. 1989;28 Suppl 1(Suppl 1):23S-30S. doi: 10.1111/j.1365-2125.1989.tb03570.x. PMID: 2572251; PMCID: PMC1379873.
3: Schutsky K, Ouyang M, Thomas SA. Xamoterol impairs hippocampus-dependent emotional memory retrieval via Gi/o-coupled β2-adrenergic signaling. Learn Mem. 2011 Aug 30;18(9):598-604. doi: 10.1101/lm.2302811. PMID: 21878527; PMCID: PMC3166789.
4: Cruickshank JM. Beta-blockers and heart failure. Indian Heart J. 2010 Mar- Apr;62(2):101-10. PMID: 21180298.
5: Furlong R, Brogden RN. Xamoterol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs. 1988 Oct;36(4):455-74. doi: 10.2165/00003495-198836040-00004. PMID: 2906865.
6: Xamoterol--more trouble than it's worth? Drug Ther Bull. 1990 Jul 9;28(14):53-4. doi: 10.1136/dtb.28.14.53. PMID: 1983395.
7: Cruickshank JM. The xamoterol experience in the treatment of heart failure. Am J Cardiol. 1993 Mar 25;71(9):61C-64C. doi: 10.1016/0002-9149(93)90088-t. PMID: 8465800.
8: Malta E, Mian MA, Raper C. The in vitro pharmacology of xamoterol (ICI 118,587). Br J Pharmacol. 1985 May;85(1):179-87. doi: 10.1111/j.1476-5381.1985.tb08845.x. PMID: 2862938; PMCID: PMC1916765.
9: Schäfers RF, Karl I, Mennicke K, Daul AE, Philipp T, Brodde OE. Ketotifen and cardiovascular effects of xamoterol following single and chronic dosing in healthy volunteers. Br J Clin Pharmacol. 1999 Jan;47(1):59-66. doi: 10.1046/j.1365-2125.1999.00854.x. PMID: 10073741; PMCID: PMC2014201.
10: James MA, Papouchado M, Channer KS, Jones JV, Marlow HF, Bastain W, Barker NP, Harry JD, Wardleworth AG. The effect of oral dosing of xamoterol on systolic time intervals in man and xamoterol plasma concentrations in heart failure patients. Br J Clin Pharmacol. 1990 Apr;29(4):447-53. doi: 10.1111/j.1365-2125.1990.tb03663.x. PMID: 2139340; PMCID: PMC1380115.
